Objectives. Helicobacter pylori infection is common and can lead to precancerous gastric lesions. Standard antibiotic therapy has a failure rate of more than 25% from antibiotic resistance. The primary aim of this observational pilot study was to test the feasibility of a large-scale clinical trial of Conifer Green Needle Complex (CGNC) to treat precancerous gastric lesions. Secondary aims were to investigate H. pylori infection, stomach function, and histopathology of the gastric mucosa. Methods. A tablet form of CGNC (extracted from Pinus sylvestris and Picea abies (L) Karst) was prescribed to 26 patients with precancerous gastric lesions (two tablets, 100 mg CGNC/tablet, three times per day for six months). Another 24 patients received no treatment. Results. Compared with control patients, CGNC-treated patients showed total or partial regression (using the quantitative Rome III diagnostic criteria) of dyspeptic symptoms (92.3%, p < 0.0001), eradication of H. pylori infection (57.1%, p < 0.03), a reduction in endoscopic signs of gastritis (92.3%, p < 0.001), an increase of pepsinogen-pepsin in the gastric juice (57.7%, p < 0.05), and total regression or reduction in the degree of intestinal metaplasia (46.2%, p < 0.05) and lymphoplasmacytic infiltration (53.8%, p < 0.05). Conclusions. This study justifies a randomised-controlled trial with CGNC in patients with atrophic gastritis.
展开▼
机译：目标。幽门螺杆菌感染很常见，可导致胃癌前病变。标准抗生素治疗的抗生素耐药性失败率超过25％。这项观察性先导研究的主要目的是测试针叶树绿针复合物（CGNC）治疗癌前胃病变的大规模临床试验的可行性。次要目的是调查幽门螺杆菌感染，胃功能和胃黏膜的组织病理学。方法。 CGNC片剂（从樟子松和云杉云杉提取）处方用于26例胃癌前病变患者（两片，每片100μgCGNC，每天三次，共六个月）。另外24名患者未接受治疗。结果。与对照组患者相比，用CGNC治疗的患者消化不良症状（92.3％，p <0.0001），根除幽门螺杆菌感染（57.1％，p <0.03）完全或部分消退（使用定量的罗马III诊断标准），胃镜的胃镜征象减少（92.3％，p <0.001），胃液中胃蛋白酶原-胃蛋白酶的增加（57.7％，p <0.05），肠上皮化生程度的完全消退或减少（46.2％， p <0.05）和淋巴浆细胞浸润（53.8％，p <0.05）。结论。这项研究证明了萎缩性胃炎患者进行CGNC随机对照试验的合理性。
展开▼
